Cho J, et al. - Considering the large-scale epidemiological studies demonstrating a protective effect of clozapine on mortality in people with schizophrenia, researchers examined how clozapine use influence all-cause mortality in treatment-resistant schizophrenia (TRS) patients. From the South London and Maudsley NHS Foundation Trust (SLAM) electronic health records (EHR), they selected a historical patient cohort sample of 2837 patients, who met criteria for TRS identifying a reduced risk of mortality in clozapine users who meet criteria for TRS. Further evidence suggested that enhancing access to clozapine in TRS may diminish the mortality gap in schizophrenia.